Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Berkshire Hathaway Inc Class B (BRK.B) vs Novartis AG (NVS) Price & Performance

Berkshire Hathaway Inc Class BTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Berkshire Hathaway Inc Class B vs Novartis AG — how do they compare? Berkshire Hathaway Inc Class B trades at $516.03, while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while Berkshire Hathaway Inc Class B pays none, and Berkshire Hathaway Inc Class B is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.

BRK.BNVS
Sector
FinancialsHealth
52-Week High
$529.65$168.62
52-Week Low
$465.39$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Berkshire Hathaway Inc Class B

BRK.B trades at $529.65, up 1.73% with strong technical momentum indicated by bullish moving averages and ADX readings. Analyst consensus is positive with 57% buy ratings. The stock is near its pivot point of $530, with support at $522 and resistance at $536. Recent financial data is unavailable in the provided snapshot.

The outlook is cautiously optimistic given technical strength and analyst support, but reliance on broader market trends and Berkshire Hathaway's diverse portfolio performance remains key. Risks include market volatility and economic shifts affecting its holdings.

Novartis AG

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Berkshire Hathaway Inc Class B

Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.

Read more on BRK.B

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS